nach oben

Current Gastroenterology Reports

Erschienen in:

01.07.2016 | Small Intestine (D Sachar, Section Editor)

Management and Complications of Short Bowel Syndrome: an Updated Review

verfasst von: Robert E. Carroll, Enrico Benedetti, Joseph P. Schowalter, Alan L. Buchman

Erschienen in: Current Gastroenterology Reports | Ausgabe 7/2016

Einloggen, um Zugang zu erhalten

Abstract

Short bowel syndrome (SBS) is defined as loss of bowel mass from surgical resection, congenital defects, or disease. Intestinal failure (IF) includes the subset of SBS unable to meet nutrition needs with enteral supplements and requires parenteral nutrition (PN). The parenteral treatment of SBS is now a half-century old. Recent pharmacologic treatment (GLP-2 analogues) has begun to make a significant impact in the care and ultimate management of these patients such that the possibility of reducing PN requirements in formerly PN-dependent patients is a now a real possibility. Finally, newer understanding and possible treatment for some of the complications related to IF have more recently evolved and will be an emphasis of this report. This review will focus on developments over the last 10 years with the goal of updating the reader to new advances in our understanding of the care and feeding of the SBS patient.

O’Keefe SJ, Buchman AL, Fishbein TM, Jeejeebhoy KN, Jeppesen PB, Shaffer J. Short bowel syndrome and intestinal failure: consensus definitions and overview. Clin Gastroenterol Hepatol. 2006;4(1):6–10. doi:10.1016/j.cgh.2005.10.002.PubMedCrossRef

Dudrick SJ, Wilmore DW, Vars HM, Rhoads JE. Long-term total parenteral nutrition with growth, development, and positive nitrogen balance. Surgery. 1968;64(1):134–42.PubMed

Buchman AL, Scolapio J, Fryer J. AGA technical review on short bowel syndrome and intestinal transplantation. Gastroenterology. 2003;124(4):1111–34. doi:10.1053/gast.2003.50139a.PubMedCrossRef

Mullady DK, O’Keefe SJ. Treatment of intestinal failure: home parenteral nutrition. Nat Clin Pract Gastroenterol Hepatol. 2006;3(9):492–504. doi:10.1038/ncpgasthep0580.PubMedCrossRef

Nightingale J, Woodward JM, Gastroenterology SBaNCotBSo. Guidelines for management of patients with a short bowel. Gut. 2006;55 Suppl 4:iv1–12.PubMedPubMedCentral

Sinha R, Trivedi D, Murphy PD, Fallis S. Small-intestinal length measurement on MR enterography: comparison with in vivo surgical measurement. AJR Am J Roentgenol. 2014;203(3):W274–9. doi:10.2214/AJR.13.11944.PubMedCrossRef

Carbonnel F, Cosnes J, Chevret S, Beaugerie L, Ngô Y, Malafosse M, et al. The role of anatomic factors in nutritional autonomy after extensive small bowel resection. JPEN J Parenter Enteral Nutr. 1996;20(4):275–80.PubMedCrossRef

Kurkchubasche AG, Rowe MI, Smith SD. Adaptation in short-bowel syndrome: reassessing old limits. J Pediatr Surg. 1993;28(8):1069–71.PubMedCrossRef

Crenn P, Messing B, Cynober L. Citrulline as a biomarker of intestinal failure due to enterocyte mass reduction. Clin Nutr. 2008;27(3):328–39. doi:10.1016/j.clnu.2008.02.005.PubMedCrossRef

10.

Sigalet DL, Martin G, Meddings J, Hartman B, Holst JJ. GLP-2 levels in infants with intestinal dysfunction. Pediatr Res. 2004;56(3):371–6. doi:10.1203/01.PDR.0000134250.80492.EC.PubMedCrossRef

11.

Ziv YH, Burrow T, Kocoshis S, Pentiuk S. Encephalopathy in a patient with short bowel syndrome: case report and discussion of the pathophysiology. JPEN J Parenter Enteral Nutr. 2014;38(4):518–20. doi:10.1177/0148607113496819.PubMedCrossRef

12.

Weale AR, Edwards AG, Bailey M, Lear PA. Intestinal adaptation after massive intestinal resection. Postgrad Med J. 2005;81(953):178–84. doi:10.1136/pgmj.2004.023846.PubMedPubMedCentralCrossRef

13.

Miskowiak J, Andersen B. Bypass revision in unsatisfactory weight loss after jejunoileal bypass for morbid obesity. Scand J Gastroenterol. 1982;17(2):317–9.PubMedCrossRef

14.

Tappenden KA. Intestinal adaptation following resection. JPEN J Parenter Enteral Nutr. 2014;38(1 Suppl):23S–31. doi:10.1177/0148607114525210.PubMedCrossRef

15.

Messing B, Crenn P, Beau P, Boutron-Ruault MC, Rambaud JC, Matuchansky C. Long-term survival and parenteral nutrition dependence in adult patients with the short bowel syndrome. Gastroenterology. 1999;117(5):1043–50.PubMedCrossRef

16.

Higuera I, Garcia-Peris P, Camblor M, Bretón I, Velasco C, Romero R, et al. Outcomes of a general hospital-based home parenteral nutrition (HPN) program; report of our experience from a 26-year period. Nutr Hosp. 2014;30(2):359–65. doi:10.3305/nh.2014.30.2.7592.PubMed

17.••

Jeppesen PB, Pertkiewicz M, Messing B, Iyer K, Seidner DL, O’keefe SJ, et al. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology. 2012;143(6):1473–81.e3. doi:10.1053/j.gastro.2012.09.007. Teduglutide is the most significant medical advance in the treatment of SBS since the development of PN.PubMedCrossRef

18.

Kelly DG, Tappenden KA, Winkler MF. Short bowel syndrome: highlights of patient management, quality of life, and survival. JPEN J Parenter Enteral Nutr. 2014;38(4):427–37. doi:10.1177/0148607113512678.PubMedCrossRef

19.

Vantini I, Benini L, Bonfante F, Talamini G, Sembenini C, Chiarioni G, et al. Survival rate and prognostic factors in patients with intestinal failure. Dig Liver Dis. 2004;36(1):46–55. doi:10.1016/j.dld.2003.09.015.PubMedCrossRef

20.

Lloyd DA, Vega R, Bassett P, Forbes A, Gabe SM. Survival and dependence on home parenteral nutrition: experience over a 25-year period in a UK referral centre. Aliment Pharmacol Ther. 2006;24(8):1231–40. doi:10.1111/j.1365-2036.2006.03106.x.PubMedCrossRef

21.

Crenn P, Rakotoanbinina B, Raynaud JJ, Thuillier F, Messing B, Melchior JC. Hyperphagia contributes to the normal body composition and protein-energy balance in HIV-infected asymptomatic men. J Nutr. 2004;134(9):2301–6.PubMed

22.

Nightingale JM. Management of patients with a short bowel. World J Gastroenterol. 2001;7(6):741–51.PubMedPubMedCentralCrossRef

23.

Messing B, Pigot F, Rongier M, Morin MC, Ndeïndoum U, Rambaud JC. Intestinal absorption of free oral hyperalimentation in the very short bowel syndrome. Gastroenterology. 1991;100(6):1502–8.PubMed

24.

Qandeel HG, Alonso F, Hernandez DJ, Madhavan S, Duenes JA, Zheng Y, et al. Peptide absorption after massive proximal small bowel resection: mechanisms of ileal adaptation. J Gastrointest Surg. 2011;15(9):1537–47. doi:10.1007/s11605-011-1581-z.PubMedPubMedCentralCrossRef

25.

Buyse M, Berlioz F, Guilmeau S, Tsocas A, Voisin T, Péranzi G, et al. PepT1-mediated epithelial transport of dipeptides and cephalexin is enhanced by luminal leptin in the small intestine. J Clin Invest. 2001;108(10):1483–94. doi:10.1172/JCI13219.PubMedPubMedCentralCrossRef

26.

Hindlet P, Bado A, Farinotti R, Buyse M. Long-term effect of leptin on H+-coupled peptide cotransporter 1 activity and expression in vivo: evidence in leptin-deficient mice. J Pharmacol Exp Ther. 2007;323(1):192–201. doi:10.1124/jpet.107.125799.PubMedCrossRef

27.

McIntyre PB, Fitchew M, Lennard-Jones JE. Patients with a high jejunostomy do not need a special diet. Gastroenterology. 1986;91(1):25–33.PubMedCrossRef

28.

Cosnes J, Evard D, Beaugerie L, Gendre JP, Le Quintrec Y. Improvement in protein absorption with a small-peptide-based diet in patients with high jejunostomy. Nutrition. 1992;8(6):406–11.PubMed

29.

Novak F, Heyland DK, Avenell A, Drover JW, Su X. Glutamine supplementation in serious illness: a systematic review of the evidence. Crit Care Med. 2002;30(9):2022–9. doi:10.1097/01.CCM.0000026106.58241.95.PubMedCrossRef

30.

Byrne TA, Wilmore DW, Iyer K, Dibaise J, Clancy K, Robinson MK, et al. Growth hormone, glutamine, and an optimal diet reduces parenteral nutrition in patients with short bowel syndrome: a prospective, randomized, placebo-controlled, double-blind clinical trial. Ann Surg. 2005;242(5):655–61.PubMedPubMedCentralCrossRef

31.

Wales PW, Nasr A, de Silva N, Yamada J. Human growth hormone and glutamine for patients with short bowel syndrome. Cochrane Database Syst Rev. 2010;6:CD006321. doi:10.1002/14651858.CD006321.pub2.PubMed

32.

Scolapio JS. Short bowel syndrome: recent clinical outcomes with growth hormone. Gastroenterology. 2006;130(2 Suppl 1):S122–6. doi:10.1053/j.gastro.2005.12.003.PubMedCrossRef

33.

Cardell RR, Badenhausen S, Porter KR. Intestinal triglyceride absorption in the rat. An electron microscopical study. J Cell Biol. 1967;34(1):123–55.PubMedPubMedCentralCrossRef

34.

Alrefai WA, Gill RK. Bile acid transporters: structure, function, regulation and pathophysiological implications. Pharm Res. 2007;24(10):1803–23. doi:10.1007/s11095-007-9289-1.PubMedCrossRef

35.

Hofmann AF, Hagey LR. Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell Mol Life Sci. 2008;65(16):2461–83. doi:10.1007/s00018-008-7568-6.PubMedCrossRef

36.

Kapral C, Wewalka F, Praxmarer V, Lenz K, Hofmann AF. Conjugated bile acid replacement therapy in short bowel syndrome patients with a residual colon. Z Gastroenterol. 2004;42(7):583–9. doi:10.1055/s-2004-813059.PubMedCrossRef

37.

Faber J, Goldstein R, Blondheim O, Stankiewicz H, Darwashi A, Bar-Maor JA, et al. Absorption of medium chain triglycerides in the stomach of the human infant. J Pediatr Gastroenterol Nutr. 1988;7(2):189–95.PubMedCrossRef

38.

Jeppesen PB, Mortensen PB. The influence of a preserved colon on the absorption of medium chain fat in patients with small bowel resection. Gut. 1998;43(4):478–83.PubMedPubMedCentralCrossRef

39.

Gray GM. Carbohydrate digestion and absorption. Role of the small intestine. N Engl J Med. 1975;292(23):1225–30. doi:10.1056/NEJM197506052922308.PubMedCrossRef

40.

Cura AJ, Carruthers A. Role of monosaccharide transport proteins in carbohydrate assimilation, distribution, metabolism, and homeostasis. Compr Physiol. 2012;2(2):863–914. doi:10.1002/cphy.c110024.PubMedPubMedCentral

41.

Hamilton KL, Butt AG. Glucose transport into everted sacs of the small intestine of mice. Adv Physiol Educ. 2013;37(4):415–26. doi:10.1152/advan.00017.2013.PubMedCrossRef

42.

Depoortere I. Taste receptors of the gut: emerging roles in health and disease. Gut. 2014;63(1):179–90. doi:10.1136/gutjnl-2013-305112.PubMedCrossRef

43.

Atia A, Girard-Pipau F, Hébuterne X, Spies WG, Guardiola A, Ahn CW, et al. Macronutrient absorption characteristics in humans with short bowel syndrome and jejunocolonic anastomosis: starch is the most important carbohydrate substrate, although pectin supplementation may modestly enhance short chain fatty acid production and fluid absorption. JPEN J Parenter Enteral Nutr. 2011;35(2):229–40. doi:10.1177/0148607110378410.PubMedCrossRef

44.

Nordgaard I, Hansen BS, Mortensen PB. Colon as a digestive organ in patients with short bowel. Lancet. 1994;343(8894):373–6.PubMedCrossRef

45.

den Besten G, Lange K, Havinga R, van Dijk TH, Gerding A, van Eunen K, et al. Gut-derived short-chain fatty acids are vividly assimilated into host carbohydrates and lipids. Am J Physiol Gastrointest Liver Physiol. 2013;305(12):G900–10. doi:10.1152/ajpgi.00265.2013.CrossRef

46.

Schiano TD, Klang MG, Quesada E, Scott F, Tao Y, Shike M. Thiamine status in patients receiving long-term home parenteral nutrition. Am J Gastroenterol. 1996;91(12):2555–9.PubMed

47.

Lakhani SV, Shah HN, Alexander K, Finelli FC, Kirkpatrick JR, Koch TR. Small intestinal bacterial overgrowth and thiamine deficiency after Roux-en-Y gastric bypass surgery in obese patients. Nutr Res. 2008;28(5):293–8. doi:10.1016/j.nutres.2008.03.002.PubMedCrossRef

48.

Justino SR, Gonçalves Dias MC, Maculevicius J, Batista de Morais M, Sing TC, Halpern A, et al. Fasting breath hydrogen concentration in short bowel syndrome patients with colon incontinuity before and after antibiotic therapy. Nutrition. 2004;20(2):187–91. doi:10.1016/j.nut.2003.10.009.PubMedCrossRef

49.

Duerksen DR, Fallows G, Bernstein CN. Vitamin B12 malabsorption in patients with limited ileal resection. Nutrition. 2006;22(11-12):1210–3. doi:10.1016/j.nut.2006.08.017.PubMedCrossRef

50.

Pedersen GA, Chakraborty S, Steinhauser AL, Traub LM, Madsen M. AMN directs endocytosis of the intrinsic factor-vitamin B(12) receptor cubam by engaging ARH or Dab2. Traffic. 2010;11(5):706–20. doi:10.1111/j.1600-0854.2010.01042.x.PubMedPubMedCentralCrossRef

51.

Renner AB, Dietrich-Ntoukas T, Jägle H. Recurrent episodes of night blindness in a patient with short bowel syndrome. Doc Ophthalmol. 2015;131(3):221–30. doi:10.1007/s10633-015-9516-8.PubMedCrossRef

52.

Braga CB, Vannucchi H, Freire CM, Marchini JS, Jordão AA, da Cunha SF. Serum vitamins in adult patients with short bowel syndrome receiving intermittent parenteral nutrition. JPEN J Parenter Enteral Nutr. 2011;35(4):493–8. doi:10.1177/0148607110386964.PubMedCrossRef

53.

Touloukian RJ, Gertner JM. Vitamin D deficiency rickets as a late complication of the short gut syndrome during infancy. J Pediatr Surg. 1981;16(3):230–5.PubMedCrossRef

54.

Margulies SL, Kurian D, Elliott MS, Han Z. Vitamin D deficiency in patients with intestinal malabsorption syndromes—think in and outside the gut. J Dig Dis. 2015;16(11):617–33. doi:10.1111/1751-2980.12283.PubMedCrossRef

55.

Jeejeebhoy K. Zinc: an essential trace element for parenteral nutrition. Gastroenterology. 2009;137(5 Suppl):S7–12. doi:10.1053/j.gastro.2009.08.014.PubMedCrossRef

56.

Ishida T, Himeno K, Torigoe Y, Inoue M, Wakisaka O, Tabuki T, et al. Selenium deficiency in a patient with Crohn’s disease receiving long-term total parenteral nutrition. Intern Med. 2003;42(2):154–7.PubMedCrossRef

57.

Blaszyk H, Wild PJ, Oliveira A, Kelly DG, Burgart LJ. Hepatic copper in patients receiving long-term total parenteral nutrition. J Clin Gastroenterol. 2005;39(4):318–20.PubMedCrossRef

58.•

Vanek VW. Review of trace mineral requirements for preterm infants: what are the current recommendations for clinical practice? Nutr Clin Pract. 2015;30(5):720–1. doi:10.1177/0884533615598965. The identification of potential toxicity of parenteral vitamins is of significance for adult and peditric PN population. This review addresses a potential safety problem with the use of these preparations. PubMedCrossRef

59.

Hardy G. Manganese in parenteral nutrition: who, when, and why should we supplement? Gastroenterology. 2009;137(5 Suppl):S29–35. doi:10.1053/j.gastro.2009.08.011.PubMedCrossRef

60.

Moukarzel A. Chromium in parenteral nutrition: too little or too much? Gastroenterology. 2009;137(5 Suppl):S18–28. doi:10.1053/j.gastro.2009.08.048.PubMedCrossRef

61.

Straus E, Yalow RS. Studies on the distribution and degradation of heptadecapeptide, big, and big big gastrin. Gastroenterology. 1974;66(5):936–43.PubMed

62.

Buchman AL, Fryer J, Wallin A, Ahn CW, Polensky S, Zaremba K. Clonidine reduces diarrhea and sodium loss in patients with proximal jejunostomy: a controlled study. JPEN J Parenter Enteral Nutr. 2006;30(6):487–91.PubMedCrossRef

63.

Nehra V, Camilleri M, Burton D, Oenning L, Kelly DG. An open trial of octreotide long-acting release in the management of short bowel syndrome. Am J Gastroenterol. 2001;96(5):1494–8. doi:10.1111/j.1572-0241.2001.03803.x.PubMedCrossRef

64.

Gómez-Herrera E, Farías-Llamas OA, Gutiérrez-de la Rosa JL, Hermosillo-Sandoval JM. The role of long-acting release (LAR) depot octreotide as adjuvant management of short bowel disease]. Cir Cir. 2004;72(5):379–86. doi:10.3201/eid1011.040428.PubMed

65.

Sato D, Morino K, Ohashi N, Ueda E, Ikeda K, Yamamoto H, et al. Octreotide improves early dumping syndrome potentially through incretins: a case report. Endocr J. 2013;60(7):847–53.PubMedCrossRef

66.

Hussaini SH, Pereira SP, Murphy GM, Kennedy C, Wass JA, Besser GM, et al. Composition of gall bladder stones associated with octreotide: response to oral ursodeoxycholic acid. Gut. 1995;36(1):126–32.PubMedPubMedCentralCrossRef

67.

Sukhotnik I, Khateeb K, Krausz MM, Sabo E, Siplovich L, Coran AG, et al. Sandostatin impairs postresection intestinal adaptation in a rat model of short bowel syndrome. Dig Dis Sci. 2002;47(9):2095–102.PubMedCrossRef

68.

Hediger MA, Turk E, Pajor AM, Wright EM. Molecular genetics of the human Na+/glucose cotransporter. Klin Wochenschr. 1989;67(17):843–6.PubMedCrossRef

69.

Wright EM, Loo DD, Hirayama BA, Turk E. Surprising versatility of Na+-glucose cotransporters: SLC5. Physiology (Bethesda). 2004;19:370–6. doi:10.1152/physiol.00026.2004.CrossRef

70.

Freedman SB, Cho D, Boutis K, Stephens D, Schuh S. Assessing the palatability of oral rehydration solutions in school-aged children: a randomized crossover trial. Arch Pediatr Adolesc Med. 2010;164(8):696–702. doi:10.1001/archpediatrics.2010.129.PubMedCrossRef

71.

Mansmann H. Lab diagnosis of magnesium deficiency. The BartterSite 2008

72.

Anast CS, Winnacker JL, Forte LR, Burns TW. Impaired release of parathyroid hormone in magnesium deficiency. J Clin Endocrinol Metab. 1976;42(4):707–17. doi:10.1210/jcem-42-4-707.PubMedCrossRef

73.

Hahn M, Raithel M, Hagel A, Biermann T, Manger B. Chronic calcium pyrophosphate crystal inflammatory arthritis induced by extreme hypomagnesemia in short bowel syndrome. BMC Gastroenterol. 2012;12:129. doi:10.1186/1471-230X-12-129.PubMedPubMedCentralCrossRef

74.

Florentin M, Elisaf MS. Proton pump inhibitor-induced hypomagnesemia: a new challenge. World J Nephrol. 2012;1(6):151–4. doi:10.5527/wjn.v1.i6.151.PubMedPubMedCentralCrossRef

75.

Thulesen J. Glucagon-like peptide 2 (GLP-2), an intestinotrophic mediator. Curr Protein Pept Sci. 2004;5(1):51–65.PubMedCrossRef

76.••

Drucker DJ, Yusta B. Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2. Annu Rev Physiol. 2014;76:561–83. doi:10.1146/annurev-physiol-021113-170317. Dr. Drucker’s cloning and characterization of GLP-2 and its cognate receptor identified the most important trophic hormone of the small intestine known to date. PubMedCrossRef

77.

Jeppesen PB, Sanguinetti EL, Buchman A, Howard L, Scolapio JS, Ziegler TR, et al. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut. 2005;54(9):1224–31. doi:10.1136/gut.2004.061440.PubMedPubMedCentralCrossRef

78.

Thulesen J, Hartmann B, Hare KJ, Kissow H, Ørskov C, Holst JJ, et al. Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice. Gut. 2004;53(8):1145–50. doi:10.1136/gut.2003.035212.PubMedPubMedCentralCrossRef

79.

Roslyn JJ, Pitt HA, Mann L, Fonkalsrud EW, DenBesten L. Parenteral nutrition-induced gallbladder disease: a reason for early cholecystectomy. Am J Surg. 1984;148(1):58–63.PubMedCrossRef

80.

Thompson JS. The role of prophylactic cholecystectomy in the short-bowel syndrome. Arch Surg. 1996;131(5):556–9. discussion 9-60.PubMedCrossRef

81.

Hutchinson R, Tyrrell PN, Kumar D, Dunn JA, Li JK, Allan RN. Pathogenesis of gall stones in Crohn’s disease: an alternative explanation. Gut. 1994;35(1):94–7.PubMedPubMedCentralCrossRef

82.

Redfern JS, Fortuner WJ. Octreotide-associated biliary tract dysfunction and gallstone formation: pathophysiology and management. Am J Gastroenterol. 1995;90(7):1042–52.PubMed

83.

Buchman AL, Moukarzel A. Metabolic bone disease associated with total parenteral nutrition. Clin Nutr. 2000;19(4):217–31. doi:10.1054/clnu.1999.0083.PubMedCrossRef

84.

Pironi L, Labate AM, Pertkiewicz M, Przedlacki J, Tjellesen L, Staun M, et al. Prevalence of bone disease in patients on home parenteral nutrition. Clin Nutr. 2002;21(4):289–96.PubMedCrossRef

85.

Braga CB, Bizari L, Suen VM, Marchini JS, Paula FJ, Cunha SF. Bone mineral density in short bowel syndrome: correlation with BMI and serum vitamins C, E and K. Arch Endocrinol Metab. 2015;59(3):252–8. doi:10.1590/2359-3997000000046.PubMedCrossRef

86.

Ament ME. Bone mineral content in patients with short bowel syndrome: the impact of parenteral nutrition. J Pediatr. 1998;132(3 Pt 1):386–8.PubMedCrossRef

87.

Tangpricha V, Luo M, Fernández-Estívariz C, Gu LH, Bazargan N, Klapproth JM, et al. Growth hormone favorably affects bone turnover and bone mineral density in patients with short bowel syndrome undergoing intestinal rehabilitation. JPEN J Parenter Enteral Nutr. 2006;30(6):480–6.PubMedCrossRef

88.

Haderslev KV, Jeppesen PB, Hartmann B, Thulesen J, Sorensen HA, Graff J, et al. Short-term administration of glucagon-like peptide-2. Effects on bone mineral density and markers of bone turnover in short-bowel patients with no colon. Scand J Gastroenterol. 2002;37(4):392–8.PubMedCrossRef

89.

Emmett M, Guirl MJ, Santa Ana CA, Porter JL, Neimark S, Hofmann AF, et al. Conjugated bile acid replacement therapy reduces urinary oxalate excretion in short bowel syndrome. Am J Kidney Dis. 2003;41(1):230–7. doi:10.1053/ajkd.2003.50012.PubMedCrossRef

90.

Finkielstein VA, Goldfarb DS. Strategies for preventing calcium oxalate stones. CMAJ. 2006;174(10):1407–9. doi:10.1503/cmaj.051517.PubMedPubMedCentralCrossRef

91.

Luman W, Shaffer JL. Prevalence, outcome and associated factors of deranged liver function tests in patients on home parenteral nutrition. Clin Nutr. 2002;21(4):337–43.PubMedCrossRef

92.

Kelly DA. Intestinal failure-associated liver disease: what do we know today? Gastroenterology. 2006;130(2 Suppl 1):S70–7. doi:10.1053/j.gastro.2005.10.066.PubMedCrossRef

93.

Fitzgibbons SC, Jones BA, Hull MA, Zurakowski D, Duro D, Duggan C, et al. Relationship between biopsy-proven parenteralnutrition-associated liver fibrosis and biochemical cholestasis in children with short bowel syndrome. J Pediatr Surg. 2010;45(1):95–9. doi:10.1016/j.jpedsurg.2009.10.020. discussion 9.PubMedPubMedCentralCrossRef

94.

Fong DG, Nehra V, Lindor KD, Buchman AL. Metabolic and nutritional considerations in nonalcoholic fatty liver. Hepatology. 2000;32(1):3–10. doi:10.1053/jhep.2000.8978.PubMedCrossRef

95.

Rollins MD, Scaife ER, Jackson WD, Meyers RL, Mulroy CW, Book LS. Elimination of soybean lipid emulsion in parenteral nutrition and supplementation with enteral fish oil improve cholestasis in infants with short bowel syndrome. Nutr Clin Pract. 2010;25(2):199–204. doi:10.1177/0884533610361477.PubMedCrossRef

96.

Xu Z, Li Y, Wang J, Wu B, Li J. Effect of omega-3 polyunsaturated fatty acids to reverse biopsy-proven parenteral nutrition-associated liver disease in adults. Clin Nutr. 2012;31(2):217–23. doi:10.1016/j.clnu.2011.10.001.PubMedCrossRef

97.

Mercer DF, Hobson BD, Fischer RT, Talmon GA, Perry DA, Gerhardt BK, et al. Hepatic fibrosis persists and progresses despite biochemical improvement in children treated with intravenous fish oil emulsion. J Pediatr Gastroenterol Nutr. 2013;56(4):364–9. doi:10.1097/MPG.0b013e31827e208c.PubMedCrossRef

98.

Matsumoto CS, Kaufman SS, Island ER, Kallakury B, Yazigi NA, Khan KM, et al. Hepatic explant pathology of pediatric intestinal transplant recipients previously treated with omega-3 fatty acid lipid emulsion. J Pediatr. 2014;165(1):59–64. doi:10.1016/j.jpeds.2014.03.034.PubMedCrossRef

99.

Klek S, Chambrier C, Singer P, Rubin M, Bowling T, Staun M, et al. Four-week parenteral nutrition using a third generation lipid emulsion (SMOFlipid)—a double-blind, randomised, multicentre study in adults. Clin Nutr. 2013;32(2):224–31. doi:10.1016/j.clnu.2012.06.011.PubMedCrossRef

100.

Buchman AL, Ament ME, Sohel M, Dubin M, Jenden DJ, Roch M, et al. Choline deficiency causes reversible hepatic abnormalities in patients receiving parenteral nutrition: proof of a human choline requirement: a placebo-controlled trial. JPEN J Parenter Enteral Nutr. 2001;25(5):260–8.PubMedCrossRef

101.

Sentongo TA, Kumar P, Karza K, Keys L, Iyer K, Buchman AL. Whole-blood-free choline and choline metabolites in infants who require chronic parenteral nutrition therapy. J Pediatr Gastroenterol Nutr. 2010;50(2):194–9. doi:10.1097/MPG.0b013e3181a93735.PubMedCrossRef

102.

Dunlop RH, Hammond PB. D-lactic acidosis of ruminants. Ann N Y Acad Sci. 1965;119(3):1109–32.PubMedCrossRef

103.

Kowlgi NG, Chhabra L. D-lactic acidosis: an underrecognized complication of short bowel syndrome. Gastroenterol Res Pract. 2015;2015:476215. doi:10.1155/2015/476215.PubMedPubMedCentralCrossRef

104.

Ku W, Lau D, Huen KF. Probiotics provoked D-lactic acidosis in short bowel syndrome: case report and literature review. H K J Paediatr. 2006;11:246–54.

105.

Winkler MF, Smith CE. Clinical, social, and economic impacts of home parenteral nutrition dependence in short bowel syndrome. JPEN J Parenter Enteral Nutr. 2014;38(1 Suppl):32S–7. doi:10.1177/0148607113517717.PubMedCrossRef

106.

Kalaitzakis E, Carlsson E, Josefsson A, Bosaeus I. Quality of life in short-bowel syndrome: impact of fatigue and gastrointestinal symptoms. Scand J Gastroenterol. 2008;43(9):1057–65. doi:10.1080/00365520802078325.PubMedCrossRef

107.

Scolapio JS, Savoy AD, Kaplan J, Burger CD, Lin SC. Sleep patterns of cyclic parenteral nutrition, a pilot study: are there sleepless nights? JPEN J Parenter Enteral Nutr. 2002;26(3):214–7.PubMedCrossRef

108.

Feagan BG, Bala M, Yan S, Olson A, Hanauer S. Unemployment and disability in patients with moderately to severely active Crohn’s disease. J Clin Gastroenterol. 2005;39(5):390–5.PubMedCrossRef

109.

Marri SR, Buchman AL. The education and employment status of patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2005;11(2):171–7.PubMedCrossRef

110.

Jeppesen PB, Pertkiewicz M, Forbes A, Pironi L, Gabe SM, Joly F, et al. Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide—analyses from a randomised, placebo-controlled study. Clin Nutr. 2013;32(5):713–21. doi:10.1016/j.clnu.2013.03.016.PubMedCrossRef

111.

Kunkel D, Basseri B, Low K, Lezcano S, Soffer EE, Conklin JL, et al. Efficacy of the glucagon-like peptide-1 agonist exenatide in the treatment of short bowel syndrome. Neurogastroenterol Motil. 2011;23(8):739–e328. doi:10.1111/j.1365-2982.2011.01723.x.PubMedCrossRef

112.

Madsen KB, Askov-Hansen C, Naimi RM, Brandt CF, Hartmann B, Holst JJ, et al. Acute effects of continuous infusions of glucagon-like peptide (GLP)-1, GLP-2 and the combination (GLP-1+GLP-2) on intestinal absorption in short bowel syndrome (SBS) patients. A placebo-controlled study. Regul Pept. 2013;184:30–9. doi:10.1016/j.regpep.2013.03.025.PubMedCrossRef

113.

Jones BA, Hull MA, Potanos KM, Zurakowski D, Fitzgibbons SC, Ching YA, et al. Report of 111 consecutive patients enrolled in the International Serial Transverse Enteroplasty (STEP) Data Registry: a retrospective observational study. J Am Coll Surg. 2013;216(3):438–46. doi:10.1016/j.jamcollsurg.2012.12.018.PubMedPubMedCentralCrossRef

114.

Bianchi A. Intestinal lengthening: an experimental and clinical review. J R Soc Med. 1984;77 Suppl 3:35–41.PubMedPubMedCentral

115.

Garcia-Roca R, Tzvetanov IG, Jeon H, Hetterman E, Oberholzer J, Benedetti E. Successful living donor intestinal transplantation in cross-match positive recipients: initial experience. World J Gastrointest Surg. 2016;8(1):101–5. doi:10.4240/wjgs.v8.i1.101.PubMedPubMedCentralCrossRef

Titel: Management and Complications of Short Bowel Syndrome: an Updated Review
verfasst von: Robert E. Carroll
Enrico Benedetti
Joseph P. Schowalter
Alan L. Buchman
Publikationsdatum: 01.07.2016
Verlag: Springer US
Erschienen in: Current Gastroenterology Reports / Ausgabe 7/2016
Print ISSN: 1522-8037
Elektronische ISSN: 1534-312X
DOI: https://doi.org/10.1007/s11894-016-0511-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Management and Complications of Short Bowel Syndrome: an Updated Review

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2016

Gastric Cancer: How Can We Reduce the Incidence of this Disease?

Recent Advances in Diverticular Disease

Immunogenetic Pathogenesis of Celiac Disease and Non-celiac Gluten Sensitivity

Practical Approaches to “Top–Down” Therapies for Crohn’s Disease

Can Technology Improve the Quality of Colonoscopy?

Eradication of Helicobacter pylori Infection

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin